IBDEI0DU ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6357,1,3,0)
 ;;=3^Bladder Disorders,Other Spec
 ;;^UTILITY(U,$J,358.3,6357,1,4,0)
 ;;=4^N32.89
 ;;^UTILITY(U,$J,358.3,6357,2)
 ;;=^87989
 ;;^UTILITY(U,$J,358.3,6358,0)
 ;;=N33.^^30^392^4
 ;;^UTILITY(U,$J,358.3,6358,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6358,1,3,0)
 ;;=3^Bladder Disorders,Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,6358,1,4,0)
 ;;=4^N33.
 ;;^UTILITY(U,$J,358.3,6358,2)
 ;;=^5015654
 ;;^UTILITY(U,$J,358.3,6359,0)
 ;;=N34.2^^30^392^105
 ;;^UTILITY(U,$J,358.3,6359,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6359,1,3,0)
 ;;=3^Urethritis
 ;;^UTILITY(U,$J,358.3,6359,1,4,0)
 ;;=4^N34.2
 ;;^UTILITY(U,$J,358.3,6359,2)
 ;;=^88231
 ;;^UTILITY(U,$J,358.3,6360,0)
 ;;=N34.1^^30^392^106
 ;;^UTILITY(U,$J,358.3,6360,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6360,1,3,0)
 ;;=3^Urethritis,Nonspec
 ;;^UTILITY(U,$J,358.3,6360,1,4,0)
 ;;=4^N34.1
 ;;^UTILITY(U,$J,358.3,6360,2)
 ;;=^5015655
 ;;^UTILITY(U,$J,358.3,6361,0)
 ;;=N39.0^^30^392^110
 ;;^UTILITY(U,$J,358.3,6361,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6361,1,3,0)
 ;;=3^Urinary Tract Infection,Site Not Spec
 ;;^UTILITY(U,$J,358.3,6361,1,4,0)
 ;;=4^N39.0
 ;;^UTILITY(U,$J,358.3,6361,2)
 ;;=^124436
 ;;^UTILITY(U,$J,358.3,6362,0)
 ;;=N31.0^^30^392^78
 ;;^UTILITY(U,$J,358.3,6362,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6362,1,3,0)
 ;;=3^Neuropathic Bladder,Uninhibited NEC
 ;;^UTILITY(U,$J,358.3,6362,1,4,0)
 ;;=4^N31.0
 ;;^UTILITY(U,$J,358.3,6362,2)
 ;;=^5015644
 ;;^UTILITY(U,$J,358.3,6363,0)
 ;;=R31.9^^30^392^58
 ;;^UTILITY(U,$J,358.3,6363,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6363,1,3,0)
 ;;=3^Hematuria,Unspec
 ;;^UTILITY(U,$J,358.3,6363,1,4,0)
 ;;=4^R31.9
 ;;^UTILITY(U,$J,358.3,6363,2)
 ;;=^5019328
 ;;^UTILITY(U,$J,358.3,6364,0)
 ;;=R31.0^^30^392^56
 ;;^UTILITY(U,$J,358.3,6364,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6364,1,3,0)
 ;;=3^Hematuria,Gross
 ;;^UTILITY(U,$J,358.3,6364,1,4,0)
 ;;=4^R31.0
 ;;^UTILITY(U,$J,358.3,6364,2)
 ;;=^5019325
 ;;^UTILITY(U,$J,358.3,6365,0)
 ;;=R31.2^^30^392^57
 ;;^UTILITY(U,$J,358.3,6365,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6365,1,3,0)
 ;;=3^Hematuria,Microscopic
 ;;^UTILITY(U,$J,358.3,6365,1,4,0)
 ;;=4^R31.2
 ;;^UTILITY(U,$J,358.3,6365,2)
 ;;=^5019327
 ;;^UTILITY(U,$J,358.3,6366,0)
 ;;=R31.1^^30^392^55
 ;;^UTILITY(U,$J,358.3,6366,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6366,1,3,0)
 ;;=3^Hematuria,Benign Essential Microscopic
 ;;^UTILITY(U,$J,358.3,6366,1,4,0)
 ;;=4^R31.1
 ;;^UTILITY(U,$J,358.3,6366,2)
 ;;=^5019326
 ;;^UTILITY(U,$J,358.3,6367,0)
 ;;=N40.0^^30^392^34
 ;;^UTILITY(U,$J,358.3,6367,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6367,1,3,0)
 ;;=3^Enlarged Prostate w/o Lower Urinary Tract Symptoms
 ;;^UTILITY(U,$J,358.3,6367,1,4,0)
 ;;=4^N40.0
 ;;^UTILITY(U,$J,358.3,6367,2)
 ;;=^5015689
 ;;^UTILITY(U,$J,358.3,6368,0)
 ;;=N40.1^^30^392^33
 ;;^UTILITY(U,$J,358.3,6368,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6368,1,3,0)
 ;;=3^Enlarged Prostate w/ Lower Urinary Tract Symptoms
 ;;^UTILITY(U,$J,358.3,6368,1,4,0)
 ;;=4^N40.1
 ;;^UTILITY(U,$J,358.3,6368,2)
 ;;=^5015690
 ;;^UTILITY(U,$J,358.3,6369,0)
 ;;=N41.0^^30^392^88
 ;;^UTILITY(U,$J,358.3,6369,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6369,1,3,0)
 ;;=3^Prostatitis,Acute
 ;;^UTILITY(U,$J,358.3,6369,1,4,0)
 ;;=4^N41.0
 ;;^UTILITY(U,$J,358.3,6369,2)
 ;;=^259106
 ;;^UTILITY(U,$J,358.3,6370,0)
 ;;=N45.1^^30^392^35
 ;;^UTILITY(U,$J,358.3,6370,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6370,1,3,0)
 ;;=3^Epididymitis
 ;;^UTILITY(U,$J,358.3,6370,1,4,0)
 ;;=4^N45.1
 ;;^UTILITY(U,$J,358.3,6370,2)
 ;;=^41396
